When government funding for science is volatile, the biggest long-term risk is losing a generation of talent. Nonprofits can provide stability by funding postdoctoral fellows and junior faculty. This shores up the scientific foundation and prevents a loss of talent that can't be undone later.

Prioritize projects that promise significant impact but face minimal resistance. High-friction projects, even if impactful, drain energy on battles rather than building. The sweet spot is in areas most people don't see yet, thus avoiding pre-emptive opposition.

Widespread adoption of preventive health measures faces a major political hurdle. Politicians on four-year election cycles are incentivized to fund programs with immediate effects, rather than long-term prevention initiatives that may take 20-30 years to show results.

Karen Levy argues that making sustainability a prerequisite for funding can be a moral failure. It's like refusing to save a drowning child today because you don't have a plan to save all future drowning children. This mindset distracts from immediate, high-impact opportunities.

CZI targets a 10-15 year time horizon for its major scientific initiatives. This is a strategic sweet spot, similar to a venture-backed company's lifecycle, which is long enough for ambitious goals but concrete enough for a team to see a project through.

The biotech landscape in Southeast Asia has strong scientific talent but lacks a mature 'translation ecosystem' (VCs, experienced operators). Founders must take on the dual role of building their company and simultaneously cultivating the surrounding infrastructure, including talent, partnerships, and public trust.

Malaria expert James Tabenderana notes that research is adopted much faster when led by national researchers. In the Sahel, studies on malaria chemoprevention were quickly implemented because local researchers, with their existing trust and relationships with ministry of health officials, could effectively bridge the gap between evidence and policy.

Stockpiling multi-strain vaccines offers a strategic deterrent. While potentially less effective than a targeted vaccine, they can protect essential workers and military personnel, ensuring society continues to function during an attack. This resilience makes a biological attack a less attractive strategy for an adversary.

Government funders like the NIH are inherently risk-averse. The ideal model is for philanthropists to provide initial capital for high-risk, transformative studies. Once a concept is proven and "de-risked," government bodies can then fund the larger-scale, long-term research.